IsoTis OrthoBiologics

IsoTis, Inc. Files Registration Statement for Public Offering

Irvine, California (ots/PRNewswire) - IsoTis, Inc. (Nasdaq: ISOT), the orthobiologics company, announced today that it has filed a Form S-1 registration statement with the Securities and Exchange Commission for a proposed public offering of its common stock. The lead underwriter for the offering is Thomas Weisel Partners LLC. William Blair & Company is acting as co-manager. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from Thomas Weisel Partners, at One Montgomery Street, Suite 3700, San Francisco, CA 94104, Tel: +1-415-364-2720. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Certain statements in this press release are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets," "could," 'may," and other words of similar meaning are intended to identify such forward-looking statements. One can also identify them by the fact that they do not relate strictly to historical or current facts. Such statements are based on the current expectations of the management of IsoTis, Inc. only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of IsoTis, Inc. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting IsoTis, Inc., including, but not limited to, failure to obtain sufficient shareholder support for the exchange offer, inability to list the IsoTis, Inc. shares on NASDAQ in a timely manner, if at all, market conditions at the time of the proposed offering and inability to obtain approval from the SEC for the offering. IsoTis, Inc. expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. ots Originaltext: IsoTis OrthoBiologics Im Internet recherchierbar: http://www.presseportal.ch Contact: For information contact IsoTis: Rob Morocco, Chief Financial Officer, +1-(949)-855-7155, robert.morocco@isotis.com; Hans Herklots, Director Investor Relations, +41-21-620-6011, hans.herklots@isotis.com

Das könnte Sie auch interessieren: